The stock of Celularity Inc (NASDAQ: CELU) has increased by 12.17% when compared to last closing price of $1.89.Despite this, the company has seen a gain of 3.41% in its stock price over the last five trading days. globenewswire.com reported 2025-07-09 that FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it entered into a strategic partnership with Fountain Life, a global leader in science-backed longevity and preventative health company, to supply stem cell therapy products manufactured and distributed by Celularity.
Is It Worth Investing in Celularity Inc (NASDAQ: CELU) Right Now?
The stock has a 36-month beta value of 0.75. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CELU is 13.81M, and at present, short sellers hold a 10.40% of that float. On July 10, 2025, the average trading volume of CELU was 70.20K shares.
CELU’s Market Performance
The stock of Celularity Inc (CELU) has seen a 3.41% increase in the past week, with a 1.92% rise in the past month, and a 52.52% gain in the past quarter. The volatility ratio for the week is 8.16%, and the volatility levels for the past 30 days are at 9.50% for CELU. The simple moving average for the past 20 days is 12.20% for CELU’s stock, with a 2.30% simple moving average for the past 200 days.
Analysts’ Opinion of CELU
Many brokerage firms have already submitted their reports for CELU stocks, with Morgan Stanley repeating the rating for CELU by listing it as a “Underweight.” The predicted price for CELU in the upcoming period, according to Morgan Stanley is $1 based on the research report published on January 30, 2023 of the previous year 2023.
H.C. Wainwright gave a rating of “Buy” to CELU, setting the target price at $15 in the report published on June 22nd of the previous year.
CELU Trading at 10.07% from the 50-Day Moving Average
After a stumble in the market that brought CELU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.39% of loss for the given period.
Stock Fundamentals for CELU
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.84 for the gross margin
The net margin for Celularity Inc stands at -1.32. The total capital return value is set at -0.49. Equity return is now at value -232.51, with -25.28 for asset returns.
Based on Celularity Inc (CELU), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.22. The debt to equity ratio resting at 3.29. The interest coverage ratio of the stock is 6.12.
Currently, EBITDA for the company is -43.71 million with net debt to EBITDA at -0.44. When we switch over and look at the enterprise to sales, we see a ratio of 1.46. The receivables turnover for the company is 4.0for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.38.
Conclusion
To sum up, Celularity Inc (CELU) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
